Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 21;15(2):e35259.
doi: 10.7759/cureus.35259. eCollection 2023 Feb.

Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy

Ankoor H Patel  1 , You Li  2 , Carlos D Minacapelli  2 , Kaitlyn Catalano  2 , Vinod Rustgi  2
Affiliations

Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy

Ankoor H Patel et al. Cureus. .

Abstract

Background Rifaximin and/or lactulose therapy is widely used in cirrhotic patients for the prevention and treatment of hepatic encephalopathy. The incidence of gastrointestinal cancers in these patients on lactulose, rifaximin, and/or combination therapy is unknown. We investigated the possible effect of lactulose and rifaximin on cancer risk in patients with cirrhosis using the MarketScan database. Methods A retrospective cohort study was conducted using the Truven Health MarketScan Commercial Claims databases from 2007-2017. An index date was defined for each participant as the earliest date of cirrhosis diagnosis. A baseline period for each participant was defined as the 12 months prior to the first medication date while the study follow-up period represented the period from the initiation of the medication to its cessation. ANOVA was used to compare all continuous measures of age and duration of medication. Wald Chi-square tests were performed to test the associations between the study groups. Results A total of 12,409 patients were included in our study. The rifaximin only cohort had the greatest reduction in risk of developing colon cancer, esophageal cancer, and stomach cancer compared to the other groups. Rifaximin reduced the risk of colon cancer and esophageal cancer by 59.42% and 70.37%, respectively, compared to patients taking lactulose only. Patients in the lactulose plus rifaximin cohort had the highest rate of development of pancreatic cancer (lactulose plus rifaximin vs rifaximin only vs lactulose only, 0.45% vs 0.24% vs 0.21%; P < 0.0001) and liver and intrahepatic bile duct cancers (11.73% vs 5.84% vs 5.49%; P < 0.0001). Conclusion Colon, esophageal, and gastric cancers had a marked incidence reduction in the rifaximin only cohort compared to the other cohorts studied.

Keywords: cancer; cirrhosis; gastrointestinal cancers; lactulose; rifaximin.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Diagram for study sample selection
See this image and copyright information in PMC

References

    1. Global epidemiology of chronic liver disease. Cheemerla S, Balakrishnan M. Clin Liver Dis (Hoboken) 2021;17:365–370. - PMC - PubMed
    1. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016. Wong T, Dang K, Ladhani S, Singal AK, Wong RJ. JAMA. 2019;321:1723–1725. - PMC - PubMed
    1. Nonalcoholic fatty liver disease: a systematic review. Rinella ME. JAMA. 2015;313:2263–2273. - PubMed
    1. Epidemiology of chronic liver diseases in the USA in the past three decades. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Gut. 2020;69:564–568. - PubMed
    1. Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004-2013. Asrani SK, Kouznetsova M, Ogola G, et al. Gastroenterology. 2018;155:719–729. - PubMed

LinkOut - more resources